{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:51:53Z","timestamp":1791503513935,"version":"4.3.4"},"reference-count":57,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473203"],"award-info":[{"award-number":["82473203"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82241232"],"award-info":[{"award-number":["82241232"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272789"],"award-info":[{"award-number":["82272789"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jtho.2026.103737","type":"journal-article","created":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T23:37:28Z","timestamp":1776901048000},"page":"103737","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1871-0598","authenticated-orcid":false,"given":"Jie","family":"Huang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhehai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanqiu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongchang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longhua","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guifang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tienan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobo","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangling","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yubiao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqiang","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baohui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenyu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haichuan","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingya","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinmin","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaofeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beilei","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingrong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shen","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunpeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2026.103737_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.jtho.2026.103737_bib2","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.jtho.2026.103737_bib3","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41568-025-00797-9","article-title":"ALK in cancer: from function to therapeutic targeting","volume":"25","author":"Voena","year":"2025","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2026.103737_bib4","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMoa1408440","article-title":"First-line crizotinib versus chemotherapy in ALK-positive lung cancer","volume":"371","author":"Solomon","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103737_bib5","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103737_bib6","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-Positive Non-Small-Cell Lung Cancer","volume":"379","author":"Camidge","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103737_bib7","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103737_bib8","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase-positive non-small cell lung cancer: A randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib9","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.jtho.2024.01.013","article-title":"Iruplinalkib (WX-0593) versus crizotinib in ALK TKI-naive locally advanced or metastatic ALK-positive NSCLC: interim analysis of a randomized, open-label, Phase 3 study (INSPIRE)","volume":"19","author":"Shi","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib10","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41392-023-01538-w","article-title":"Envonalkib versus crizotinib for treatment-naive ALK-positive non-small cell lung cancer: a randomized, multicenter, open-label, phase III trial","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.jtho.2026.103737_bib11","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S1470-2045(18)30649-1","article-title":"Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study","volume":"19","author":"Solomon","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib12","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.1200\/JCO.24.00581","article-title":"Lorlatinib versus crizotinib in patients with advanced ALK-positive non-small cell lung cancer: 5-year outcomes from the Phase III CROWN study","volume":"42","author":"Solomon","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib13","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41573-023-00703-8","article-title":"Deuterium in drug discovery: progress, opportunities and challenges","volume":"22","author":"Di Martino","year":"2023","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jtho.2026.103737_bib14","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.jtho.2024.11.010","article-title":"Safety, efficacy, and biomarker analysis of deulorlatinib (TGRX-326) in anaplastic lymphoma kinase-positive NSCLC: a multicenter, open-label, Phase 1\/1b trial","volume":"20","author":"Zhao","year":"2025","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib15","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1093\/bioinformatics\/btp324","article-title":"Fast and accurate short read alignment with Burrows-Wheeler transform","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtho.2026.103737_bib16","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","article-title":"Fast and accurate long-read alignment with Burrows-Wheeler transform","volume":"26","author":"Li","year":"2010","journal-title":"Bioinformatics"},{"issue":"suppl 23","key":"10.1016\/j.jtho.2026.103737_bib17","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12859-019-3280-9","article-title":"Gencore: an efficient tool to generate consensus reads for error suppressing and duplicate removing of NGS data","volume":"20","author":"Chen","year":"2019","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.jtho.2026.103737_bib18","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1101\/gr.129684.111","article-title":"VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing","volume":"22","author":"Koboldt","year":"2012","journal-title":"Genome Res"},{"key":"10.1016\/j.jtho.2026.103737_bib19","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkq603","article-title":"ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data","volume":"38","author":"Wang","year":"2010","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.jtho.2026.103737_bib20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.7150\/ijbs.24626","article-title":"GeneFuse: detection and visualization of target gene fusions from DNA sequencing data","volume":"14","author":"Chen","year":"2018","journal-title":"Int J Biol Sci"},{"key":"10.1016\/j.jtho.2026.103737_bib21","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1093\/bioinformatics\/btu549","article-title":"FACTERA: a practical method for the discovery of genomic rearrangements at breakpoint resolution","volume":"30","author":"Newman","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtho.2026.103737_bib22","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1093\/bioinformatics\/bts272","article-title":"BreakFusion: targeted assembly-based identification of gene fusions in whole transcriptome paired-end sequencing data","volume":"28","author":"Chen","year":"2012","journal-title":"Bioinformatics"},{"key":"10.1016\/j.jtho.2026.103737_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004873","article-title":"CNVkit: genome-wide copy number detection and visualization from targeted DNA sequencing","volume":"12","author":"Talevich","year":"2016","journal-title":"PLOS Comput Biol"},{"key":"10.1016\/j.jtho.2026.103737_bib24","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.lungcan.2020.10.024","article-title":"Phase 1\/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: results from ASCEND-6","volume":"150","author":"Wu","year":"2020","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jtho.2026.103737_bib25","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/annonc\/mdy121","article-title":"Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study","volume":"29","author":"Novello","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib26","doi-asserted-by":"crossref","first-page":"2385","DOI":"10.1056\/NEJMoa1214886","article-title":"Crizotinib versus chemotherapy in advanced ALK-positive lung cancer","volume":"368","author":"Shaw","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtho.2026.103737_bib27","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.annonc.2021.02.012","article-title":"Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs","volume":"32","author":"Felip","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jtho.2022.02.014","article-title":"Lorlatinib for previously treated ALK-positive advanced NSCLC: primary efficacy and safety from a Phase 2 study in People\u2019s Republic of China","volume":"17","author":"Lu","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2014.08.2364","article-title":"Impact of brain metastases on quality of life and estimated life expectancy in patients with advanced non-small cell lung cancer","volume":"17","author":"Roughley","year":"2014","journal-title":"Value Health"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2026.103737_bib31","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.3747\/co.25.3733","article-title":"Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options?","volume":"25","author":"Abdallah","year":"2018","journal-title":"Curr Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2015.01.020","article-title":"Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers","volume":"88","author":"Rangachari","year":"2015","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jtho.2026.103737_bib33","doi-asserted-by":"crossref","first-page":"3593","DOI":"10.1200\/JCO.21.02278","article-title":"Post hoc analysis of lorlatinib intracranial efficacy and safety in patients with ALK-positive advanced non-small-cell lung cancer from the Phase III CROWN study","volume":"40","author":"Solomon","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib34","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.18.02236","article-title":"ALK resistance mutations and efficacy of lorlatinib in advanced anaplastic lymphoma kinase-positive non-small-cell lung cancer","volume":"37","author":"Shaw","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib35","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1200\/JCO.2017.76.2294","article-title":"Impact of EML4-ALK variant on resistance mechanisms and clinical outcomes in ALK-positive lung cancer","volume":"36","author":"Lin","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib36","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2021.06.012","article-title":"Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC","volume":"158","author":"Zhang","year":"2021","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"key":"10.1016\/j.jtho.2026.103737_bib37","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1093\/annonc\/mdw693","article-title":"Differential protein stability and clinical responses of EML4-ALK fusion variants to various ALK inhibitors in advanced ALK-rearranged non-small cell lung cancer","volume":"28","author":"Woo","year":"2017","journal-title":"Ann Oncol"},{"issue":"9","key":"10.1016\/j.jtho.2026.103737_bib38","doi-asserted-by":"crossref","first-page":"S432","DOI":"10.1016\/j.jtho.2022.07.750","article-title":"EP08.02-068 ALK-dependent resistance mechanism to ensartinib differs between the ALK fusion subtypes variant 1 (V1) and variant 3 (V3)","volume":"17","author":"Huang","year":"2022","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib39","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1158\/2159-8290.CD-16-0596","article-title":"Molecular mechanisms of resistance to First- and second-generation ALK inhibitors in ALK-rearranged lung cancer","volume":"6","author":"Gainor","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jtho.2026.103737_bib40","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jtho.2019.10.015","article-title":"ALK mutation status before and after alectinib treatment in locally advanced or metastatic ALK-positive NSCLC: pooled analysis of two prospective trials","volume":"15","author":"No\u00e9","year":"2020","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib41","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK tyrosine kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes from the GuardantINFORM database","volume":"19","author":"Parikh","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib42","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib43","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3003316","article-title":"Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers","volume":"4","author":"Katayama","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2026.103737_bib44","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1093\/annonc\/mdy333","article-title":"Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer","volume":"29","author":"Kron","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.9517","article-title":"Correlation of baseline molecular and clinical variables with ALK inhibitor efficacy in ALTA-1L","volume":"38","author":"Camidge","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib46","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.jtho.2021.01.1615","article-title":"Decoding the evolutionary response to ensartinib in patients with ALK-positive NSCLC by dynamic circulating tumor DNA sequencing","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib47","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/s41467-023-38195-0","article-title":"Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed\/refractory ALK-driven neuroblastoma","volume":"14","author":"Berko","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.jtho.2026.103737_bib48","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1158\/1078-0432.CCR-20-2853","article-title":"Proteasome inhibition overcomes ALK-TKI resistance in ALK-Rearranged\/TP53-mutant NSCLC via Noxa expression","volume":"27","author":"Tanimoto","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103737_bib49","doi-asserted-by":"crossref","first-page":"2535","DOI":"10.1158\/1078-0432.CCR-19-3906","article-title":"MET alterations are a recurring and actionable resistance mechanism in ALK-positive lung cancer","volume":"26","author":"Dagogo-Jack","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103737_bib50","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/nm.3667","article-title":"Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer","volume":"20","author":"Lovly","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.jtho.2026.103737_bib51","doi-asserted-by":"crossref","first-page":"6219","DOI":"10.1158\/1078-0432.CCR-12-0392","article-title":"Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer","volume":"18","author":"Tanizaki","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2026.103737_bib52","doi-asserted-by":"crossref","first-page":"e43","DOI":"10.1038\/oncsis.2013.7","article-title":"The EGFR family members sustain the neoplastic phenotype of ALK+ lung adenocarcinoma via EGR1","volume":"2","author":"Voena","year":"2013","journal-title":"Oncogenesis"},{"key":"10.1016\/j.jtho.2026.103737_bib53","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ccr.2014.05.019","article-title":"Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells","volume":"26","author":"Lee","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2026.103737_bib54","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41416-021-01642-0","article-title":"Genetic and epigenetic regulation of the NRF2-KEAP1 pathway in human lung cancer","volume":"126","author":"Cami\u00f1a","year":"2022","journal-title":"Br J Cancer"},{"key":"10.1016\/j.jtho.2026.103737_bib55","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ebiom.2016.04.017","article-title":"Implications of genetic and epigenetic alterations of CDKN2A (p16(INK4a)) in cancer","volume":"8","author":"Zhao","year":"2016","journal-title":"EBiomedicine"},{"key":"10.1016\/j.jtho.2026.103737_bib56","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.jtho.2018.12.014","article-title":"Natural history and factors associated with overall survival in Stage IV ALK-rearranged non-small cell lung cancer","volume":"14","author":"Pacheco","year":"2019","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib57","doi-asserted-by":"crossref","first-page":"S1634","DOI":"10.1016\/j.annonc.2024.10.662","article-title":"629MO ALESIA 7-year update: Alectinib vs crizotinib in Asian patients (pts) with treatment-na\u00efve advanced ALK+ non-small cell lung cancer (NSCLC)","volume":"35","author":"Zhou","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2026.103737_bib58","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/j.jtho.2024.11.021","article-title":"Final overall survival and long-term safety of lorlatinib in patients with ALK-positive NSCLC from the pivotal Phase 2 study: a brief report","volume":"20","author":"Ou","year":"2025","journal-title":"J Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086426001905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T23:23:28Z","timestamp":1791501808000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086426001905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":57,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1556086426001905"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103737","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2026.103737","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}],"article-number":"103737"}}